Pittsburgh to Build New Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

PITTSBURGH-To accommodate the growth of the University of Pittsburgh Cancer Institute’s (UPCI’s) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCI’s clinical programs and scientific investigations.

PITTSBURGH—To accommodate the growth of the University of Pittsburgh Cancer Institute’s (UPCI’s) treatment and research activities, the UPMC Health System will build a 295,000 square-foot integrated facility on the UPMC Shadyside campus. This $104 million building will serve as the hub for UPCI’s clinical programs and scientific investigations.

UPCI includes more than 600 scientists and health care professionals in more than 30 disciplines. It is the only NCI-designated comprehensive cancer center in western Pennsylvania.

“This new building symbolizes the commitment of the UPMC Health System to combat this disease, which touches every family and which is the second-leading cause of death in the United States,” said Jeffrey Romoff, president of the UPMC.

The new building will more than double current research space and allow for the recruitment of 250 new scientists and clinicians. Groundbreaking on the building will begin in the spring of this year.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content